Drug record
What four public record sets show for insulin lispro. Saved Nov 10, 2026.
| Shortage | Not on the FDA shortage list | Details |
|---|---|---|
| Pharmacy cost | Brand prices only, see table | Details |
| Medicare Part D, 2024 | $971.4 million | Details |
| FDA recall records | 4 | Details |
Whether the FDA lists this drug as in short supply.
2 products being discontinued. A maker has told the FDA it will stop making these. That is one maker leaving, not a shortage of the drug:
The list changes daily, and it covers the national supply. A pharmacy near you can be out of a drug that is not listed, or have one that is. See today's status.
The national average price retail pharmacies pay to buy it (NADAC).
| Product as surveyed | Type | Pharmacy pays | For 30 | Price since |
|---|---|---|---|---|
| INSULIN LISPRO 100 UNIT/ML KWIKPEN | Generic | $10.19 per mL | — | Oct 21, 2026 |
| INSULIN LISPRO 100 UNIT/ML VL | Generic | $2.40 per mL | — | Oct 21, 2026 |
| INSULIN LISPRO JR 100 UNIT/ML KWIKPEN | Generic | $10.19 per mL | — | Oct 21, 2026 |
| INSULIN LISPRO MIX 75-25 KWKPN | Generic | $10.20 per mL | — | Oct 21, 2026 |
| ADMELOG 100 UNIT/ML VIAL | Brand | $9.39 per mL | — | Oct 21, 2026 |
| ADMELOG SOLOSTAR 100 UNIT/ML | Brand | $12.11 per mL | — | Oct 21, 2026 |
| HUMALOG 100 UNIT/ML CARTRIDGE | Brand | $9.79 per mL | — | Oct 21, 2026 |
| HUMALOG 100 UNIT/ML KWIKPEN | Brand | $10.16 per mL | — | Oct 21, 2026 |
| HUMALOG 100 UNIT/ML VIAL | Brand | $6.36 per mL | — | Oct 21, 2026 |
| HUMALOG 200 UNIT/ML KWIKPEN | Brand | $20.31 per mL | — | Oct 21, 2026 |
| HUMALOG JR 100 UNIT/ML KWIKPEN | Brand | $10.16 per mL | — | Oct 21, 2026 |
| HUMALOG MIX 50-50 KWIKPEN | Brand | $10.15 per mL | — | Oct 21, 2026 |
| HUMALOG MIX 75-25 KWIKPEN | Brand | $10.16 per mL | — | Oct 21, 2026 |
| HUMALOG MIX 75-25 VIAL | Brand | $8.15 per mL | — | Oct 21, 2026 |
| HUMALOG TEMPO PEN 100 UNIT/ML | Brand | $10.13 per mL | — | Jun 17, 2026 |
| LYUMJEV 100 UNIT/ML KWIKPEN | Brand | $10.15 per mL | — | Oct 21, 2026 |
| LYUMJEV 100 UNIT/ML VIAL | Brand | $7.87 per mL | — | Oct 21, 2026 |
| LYUMJEV 200 UNIT/ML KWIKPEN | Brand | $20.28 per mL | — | Oct 21, 2026 |
| LYUMJEV TEMPO PEN 100 UNIT/ML | Brand | $10.14 per mL | — | Feb 1, 2026 |
This is not your price. NADAC is the national average that retail pharmacies pay to buy the drug, from the Medicaid survey for the week of Nov 11, 2026. What you pay adds the pharmacy's markup and dispensing fee and depends on your insurance or any discount card. "For 30" is shown only for products priced per tablet or capsule. Brand prices here are before any rebates.
Medicare Part D spending by product, from the latest annual file (2024).
In 2024, Medicare Part D plans and their members paid $971.4 million for the 14 products below. That is down 48% from $1.87 billion in 2020.
| Product | 2024 spending | People | Per prescription | Per person, year | 2020 spending |
|---|---|---|---|---|---|
| Humalog Kwikpen U-100 Insulin Lispro | $334.3 million | 447,128 | $240.18 | $747.74 | $1.05 billion |
| Humalog Kwikpen U-200 Insulin Lispro | $228.0 million | 45,830 | $1,426.07 | $4,975.46 | $154.5 million |
| Insulin Lispro Kwikpen U-100 Insulin Lispro | $154.4 million | 283,488 | $182.19 | $544.76 | $141.6 million |
| Humalog Insulin Lispro | $98.4 million | 149,275 | $192.55 | $659.30 | $449.3 million |
| Lyumjev Kwikpen U-100 Insulin Lispro-Aabc | $56.0 million | 22,655 | $766.17 | $2,472.90 | $326,193 |
| Admelog Solostar Insulin Lispro | $34.0 million | 50,864 | $223.59 | $668.28 | $5.8 million |
| Lyumjev Insulin Lispro-Aabc | $19.9 million | 5,449 | $1,108.43 | $3,657.07 | $193,210 |
| Insulin Lispro Insulin Lispro | $17.5 million | 106,242 | $58.20 | $164.66 | $55.8 million |
| Lyumjev Kwikpen U-200 Insulin Lispro-Aabc | $13.7 million | 2,432 | $1,627.12 | $5,621.99 | $49,352 |
| Admelog Insulin Lispro | $9.8 million | 16,113 | $211.63 | $610.84 | $2.5 million |
| Humalog Junior Kwikpen Insulin Lispro | $3.1 million | 6,564 | $179.34 | $466.75 | $6.1 million |
| Insulin Lispro Junior Kwikpen Insulin Lispro | $1.6 million | 4,333 | $153.51 | $362.56 | $325,269 |
| Lyumjev Tempo Pen U-100 Insulin Lispro-Aabc | $341,964 | 211 | $840.21 | $1,620.68 | — |
| Humalog Tempo Pen U-100 Insulin Lispro | $225,263 | 614 | $172.09 | $366.88 | — |
Spending is the gross amount paid at the pharmacy by Part D plans and patients, before manufacturer rebates, which can be large for brand drugs. The same person can use more than one product, so people are not added up across rows. A dash means the file suppresses a small number or has no figure for that year. Not counted here, combination products that contain it: Humalog Mix 50-50, Humalog Mix 50-50 Kwikpen, Humalog Mix 75-25, Humalog Mix 75-25 Kwikpen, Insulin Lispro Protamine Mix.
Recalls reported to the FDA that name this drug.
The FDA has 4 recall records that name insulin lispro in the product description (1 Class I · 3 Class II). 2 are still marked ongoing.
Sterile Diluent, HUMALOG U-100 (insulin lispro injection), HUMULIN R U-100 REGULAR (insulin human injection), Insulin Lispro Injection u-100, 10 mL, Use ONLY with Insulins listed on carton, Marketed by: Lilly USA, LLC, Indianapolis, IN 46285. NDC: 0002-0800-01
Reason: CGMP Deviations
Admelog, insulin lispro injection, 100 units/mL (U-100), 3mL multi-dose vial, Rx Only, Sanofi-Aventis U.S. LLC, Bridgewater, NJ 08807 A Sanofi Company. NDC 0024-5926-05
Reason: Lack of Assurance of Sterility: Malformed crimped collar seal
Humalog KwikPen, Insulin lispro injection, U-100, 100 units per mL, 5x3 mL Prefilled Pens per box, Marketed by Lilly USA, LLC, Indianapolis, IN 46285, Box NDC 0002-8799-59, Pen NDC 002-7516-59
Reason: TEMPERATURE ABUSE: Products were exposed to temperatures outside of the products labeled storage conditions due to inclement weather.
Admelog Solostar (insulin lispro injection), 100 units/ mL (U-100) injection, packaged in 3mL prefilled pens, 1 pen per box, Rx only, Physician Sample - Not For Sale, Sanofi-Aventis U.S. LLC, Bridgewater, NJ 08807, NDC 0024-5925-00
Reason: Temperature Abuse: Product samples of Admelog may not have been shipped at proper temperature.
A recall covers specific lots from one company, not every bottle of the drug. Records include combination products and compounded versions that name this ingredient. Class I is the most serious: use could cause serious harm. Class II may cause temporary or reversible harm. Class III is unlikely to cause harm. To check a bottle, match the lot number on the label. See the live list. Do not stop a medicine because of a recall without asking your pharmacist.
These are saved records as of Nov 10, 2026; the sources update daily to yearly. For current figures open the live report for insulin lispro. This page is public-record information, not medical advice.